Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KLARITY-1: KIO-104 in Macular Edema
NCT06825702Phase 2Recruiting
- Sponsor
- Kiora Pharmaceuticals
- Start
- May 2025
- Primary completion
- Nov 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PaniDrop in macular edema, sponsored by Kiora Pharmaceuticals. Started May 2025; status: recruiting.
02
Drugs
PaniDrop
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT06825702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825702.